Polycystic ovary syndrome (PCOS) is a widespread condition affecting women of reproductive age. A new class of medications called incretins (GLP1RAs) provides new opportunities for reducing obesity, hyperandrogenism, and insulin resistance in these patients. Promising results have been achieved, including metabolic improvements and benefits in women with PCOS using different GLP1RAs.
No takes yet. Share an insight, caveat, or question.
Mauri José Piazza (2025) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: